News | August 10, 2024
Biocon posts Q1 FY25 PAT higher at Rs. 660 Cr
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Subscribe To Our Newsletter & Stay Updated
